Literature DB >> 33466381

Does Antibody Stabilize the Ligand Binding in GP120 of HIV-1 Envelope Protein? Evidence from MD Simulation.

Shalini Yadav1, Vishnudatt Pandey2, Rakesh Kumar Tiwari2, Rajendra Prasad Ojha2, Kshatresh Dutta Dubey1.   

Abstract

CD4-mimetic HIV-1 entry inhibitors are small sized molecules which imitate similar conformational flexibility, in gp120, to the CD4 receptor. However, the mechanism of the conformational flexibility instigated by these small sized inhibitors is little known. Likewise, the effect of the antibody on the function of these inhibitors is also less studied. In this study, we present a thorough inspection of the mechanism of the conformational flexibility induced by a CD4-mimetic inhibitor, NBD-557, using Molecular Dynamics Simulations and free energy calculations. Our result shows the functional importance of Asn425 in substrate induced conformational dynamics in gp120. The MD simulations of Asn425Gly mutant provide a less dynamic gp120 in the presence of NBD-557 without incapacitating the binding enthalpy of NBD-557. The MD simulations of complexes with the antibody clearly show the enhanced affinity of NBD-557 due to the presence of the antibody, which is in good agreement with experimental Isothermal Titration Calorimetry results (Biochemistry2006, 45, 10973-10980).

Entities:  

Keywords:  HIV-entry inhibitor; MD simulations; conformational mechanism; free energy calculations

Mesh:

Substances:

Year:  2021        PMID: 33466381      PMCID: PMC7796314          DOI: 10.3390/molecules26010239

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  31 in total

1.  Ending the HIV-AIDS Pandemic--Follow the Science.

Authors:  Anthony S Fauci; Hilary D Marston
Journal:  N Engl J Med       Date:  2015-12-01       Impact factor: 91.245

2.  Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald.

Authors:  Romelia Salomon-Ferrer; Andreas W Götz; Duncan Poole; Scott Le Grand; Ross C Walker
Journal:  J Chem Theory Comput       Date:  2013-08-20       Impact factor: 6.006

Review 3.  Recent advances in protein-ligand interactions: molecular dynamics simulations and binding free energy.

Authors:  Kshatresh Dutta Dubey; Rakesh Kumar Tiwari; Rajendra Prasad Ojha
Journal:  Curr Comput Aided Drug Des       Date:  2013-12       Impact factor: 1.606

Review 4.  Past, present and future: 30 years of HIV research.

Authors:  Françoise Barré-Sinoussi; Anna Laura Ross; Jean-François Delfraissy
Journal:  Nat Rev Microbiol       Date:  2013-10-28       Impact factor: 60.633

5.  VMD: visual molecular dynamics.

Authors:  W Humphrey; A Dalke; K Schulten
Journal:  J Mol Graph       Date:  1996-02

6.  Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors.

Authors:  P L Jones; T Korte; R Blumenthal
Journal:  J Biol Chem       Date:  1998-01-02       Impact factor: 5.157

7.  Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41.

Authors:  I Muñoz-Barroso; S Durell; K Sakaguchi; E Appella; R Blumenthal
Journal:  J Cell Biol       Date:  1998-01-26       Impact factor: 10.539

Review 8.  HIV-1 entry inhibitors: an overview.

Authors:  Daniel R Kuritzkes
Journal:  Curr Opin HIV AIDS       Date:  2009-03       Impact factor: 4.283

9.  Crystal structures of HIV-1 gp120 envelope glycoprotein in complex with NBD analogues that target the CD4-binding site.

Authors:  Young Do Kwon; Judith M LaLonde; Yongping Yang; Mark A Elban; Akihiro Sugawara; Joel R Courter; David M Jones; Amos B Smith; Asim K Debnath; Peter D Kwong
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

10.  Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry.

Authors:  Rachid Sougrat; Alberto Bartesaghi; Jeffrey D Lifson; Adam E Bennett; Julian W Bess; Daniel J Zabransky; Sriram Subramaniam
Journal:  PLoS Pathog       Date:  2007-05-04       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.